Literature DB >> 9818334

Photorefractive keratectomy for astigmatism greater than -2.00 diopters in eyes with low, high, or extreme myopia.

J S Lee1, B S Oum, B J Lee, S H Lee.   

Abstract

PURPOSE: To assess the efficacy of excimer laser photorefractive astigmatic keratectomy (PARK) in correcting astigmatism of more than -2.00 diopters (D) in eyes with low, high, and extreme myopia.
SETTING: Pusan National University Hospital, Pusan, Korea.
METHODS: Eighty-five patients (110 eyes) whose spherical error ranged from -3.00 to -13.00 D and cylinder ranged from -2.00 to -5.50 D had PARK with a VISX Twenty-Twenty excimer laser; follow-up was 6 months. All cases of myopic astigmatism were treated using the elliptical method and multizone ablation technique. Eyes were divided into 3 groups: low myopia, less than 6.00 D (n = 47); high myopia, from 6.25 to 10.00 D (n = 43); extreme myopia, over 10.25 D (n = 20). Alpins vector analysis was used to calculate the astigmatic change.
RESULTS: By vector analysis, the success rate of astigmatic correction was more predictable in the low and high myopia groups than in the extreme myopia group (P < .05). There was little improvement in astigmatism in the extreme myopia group.
CONCLUSION: Using PARK to correct astigmatism greater than -2.00 D in eyes with myopia less than -10.00 D tended to result in undercorrection; astigmatic correction in eyes with myopia over 10.25 D was minimal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818334     DOI: 10.1016/s0886-3350(98)80166-1

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

Review 1.  Refractive surgery.

Authors:  P J McDonnell
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Accuracy of Intraocular Lens Power Formulas Involving 148 Eyes with Long Axial Lengths: A Retrospective Chart-Review Study.

Authors:  Chong Chen; Xian Xu; Yuyu Miao; Gaoxin Zheng; Yong Sun; Xun Xu
Journal:  J Ophthalmol       Date:  2015-12-17       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.